Avinger (AVGR) Bounces-Back on Trial Outcomes; Teradyne’s (TER) Profit Figures Surpass Estimates
Avinger Inc. (Nasdaq:AVGR) shares soared more than 20% in after-hours trading Wednesday as the company said that 2-year follow-up data demonstrated that the pivotal trial evaluating the safety and effectiveness of its Pantheris lumivascular atherectomy system in peripheral artery disease patients successfully met its endpoints.
AVGR stock finished the regular session in positive territory by 9.52% (or +$0.20) at $2.30 with a total volume of 566,199 shares traded.
Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease, has 22.80M shares outstanding and AVGR stock 52-week range is between $2.00 and $17.89 per share. At close on Wednesday, the commercial-stage medical device company had a market capitalization of $52.45M
Shares of Teradyne, Inc. (NYSE:TER) surged over 7% to touch a new 52-week high in the extended session Wednesday after the company delivered in its quarterly financial results profit and revenue numbers well-above Wall Street analysts’ expectations.
For its fourth quarter fiscal 2016, Teradyne posted revenue of $380 million, a 19.5% increase year over year, and non-GAAP net income of $64.6 million, or $0.32 per diluted share, compared to non-GAAP net income of $26.1 million, or $0.13 per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of $0.22 earnings per share on revenues of $348.01 million for the period.
TER stock closed at $27.20, up $0.67 (or +2.53%) and 3.77M of its shares changed hands during the day, representing a large increase in activity versus its average volume (3m) of 2.17M shares.
Teradyne, which designs, develops, manufactures, and sells automatic test equipment, has 201.22M shares outstanding, market capitalization (intraday) of $5.47B and TER stock one-year range is from $17.34 to $27.29 per share.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/